Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

FDA Lifts Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept Plus Pembrolizumab in Advanced Malignancies

May 24th 2022

The FDA has lifted a partial clinical hold on the phase 1 NEON-2 trial investigating the use of davoceticept in combination with pembrolizumab in adult patients with advanced solid tumors or lymphoma.

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic Melanoma

May 23rd 2022

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma

May 20th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection.

TLR9 Agonist Vidutolimod Shows Promise in Combination With Pembrolizumab in PD-1–Refractory Melanoma

May 19th 2022

The combination of intratumoral vidutolimod and intravenous pembrolizumab demonstrated promising clinical activity in patients with PD-1 refractory melanoma.

Closing Remarks on the Treatment of Patients With Metastatic Melanoma

May 17th 2022

Experts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson discuss additional second- and third-line treatment options.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma

May 13th 2022

The combination of sotigalimab and nivolumab elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial.

Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab

May 11th 2022

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs

May 11th 2022

Dr Michael Atkins and Dr Evan Lipson highlight some of the current unmet needs in the treatment of patients with metastatic melanoma.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors

May 5th 2022

Experts discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab

May 5th 2022

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians associated with the doublet, and the potential next steps for this therapy in melanoma.

Dr. Edington on the Utilization of TVEC Therapy in Melanoma

April 28th 2022

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

Dr. Kirkwood on the Use of Ipilimumab/Nivolumab in Melanoma With Brain Metastases

April 26th 2022

John M. Kirkwood, MD, discusses the utilization of ipilimumab and nivolumab in patients with melanoma with brain metastases.

First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile

April 26th 2022

Dr Michael Atkins and Dr Evan Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.

The Current State of Metastatic Melanoma

April 26th 2022

Dr Evan Lipson provides a brief overview of metastatic melanoma including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.

Dr. Edington on the Utilization of TIL Therapy in Melanoma

April 21st 2022

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma

April 21st 2022

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.